U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C29H32ClN3O4.ClH
Molecular Weight 558.496
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Elomotecan hydrochloride

SMILES

Cl.CC[C@@]1(O)CC(=O)OCC2=C1C=C3N(CC4=C(CN5CCC(C)CC5)C6=C(C=C(Cl)C(C)=C6)N=C34)C2=O

InChI

InChIKey=OLYFGLXPXPABOP-XXIQNXCHSA-N
InChI=1S/C29H32ClN3O4.ClH/c1-4-29(36)12-26(34)37-15-21-22(29)10-25-27-20(14-33(25)28(21)35)19(13-32-7-5-16(2)6-8-32)18-9-17(3)23(30)11-24(18)31-27;/h9-11,16,36H,4-8,12-15H2,1-3H3;1H/t29-;/m1./s1

HIDE SMILES / InChI

Molecular Formula C29H32ClN3O4
Molecular Weight 522.035
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Elomotecan (BN 80927), a homocamptothecin derivative, inhibits both topoisomerase I and topoisomerase II mediated DNA relaxation. It potently inhibits proliferation of human tumor cells in vitro and in vivo. Elomotecan was being developed for the treatment of solid tumors.

Originator

Approval Year

PubMed

Patents

Sample Use Guides

In Vivo Use Guide
Phase I study. Elomotecan was administered as a 30-min intravenous infusion at doses ranging from 1.5 to 75 mg once every 3 weeks to 56 patients with advanced solid tumors. Plasma concentration data and adverse effects were modeled using the population approach.
Route of Administration: Intravenous
In Vitro Use Guide
The antiproliferative activity of elomotecan (BN 80927) was determined on various human tumor cell lines from a diverse set of target organs, including leukemia and solid tumors (colon, prostate, ovary, lung, bladder, and breast cell lines). BN80927 was an antiproliferative agent on all of the cell lines tested. On this set of cell lines, BN80927 has IC50 values 2–81 nM.
Substance Class Chemical
Record UNII
5WM1F45I4Y
Record Status Validated (UNII)
Record Version